Recruiting Cancer Clinical Trials

ARTEMIDE

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Nonsmall Cell Lung Cancer
Description: This study is testing two different cancer medicines to see which one works better as the first treatment for people who have a type of lung cancer called metastatic non‑small cell lung cancer (NSCLC) with high PD‑L1 levels.
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information

ETOP ADOPT

An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Description: This international study tests if adding durvalumab (immunotherapy) after surgery, following chemo-immunotherapy before surgery, helps patients with resectable Stage IIB-IIIB lung cancer live longer without cancer returning.
Study Phase: Phase 3
Principal Investigator: Prof Patrick Forde
Further information

ETOP ARCH

A randomised phase III trial of adjuvant cemiplimab in patients with resected stage II-IIIA NSCLC who have not received prior adjuvant chemotherapy
Description: This Phase 3 study is testing whether the medicine cemiplimab can help prevent lung cancer from returning in people with Stage II–IIIA non‑small cell lung cancer who have had their tumour removed by surgery. The people in the study have not had chemotherapy after surgery.
Study Phase: Phase 3
Principal Investigator: Prof Patrick Forde
Further information

HARMONi-3 (SMT112-3003)

A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer
Description: 1st Line Metastatic Squamous NSCLC
Study Phase: Phase 3
Principal Investigator: Prof Patrick Forde
Further information

Krascendo-2

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-POSITIVE, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Description: This Phase 3 study is comparing two treatment options for people with advanced or metastatic non‑squamous lung cancer that has a KRAS G12C mutation. One group will get the medicines divarasib and pembrolizumab, and the other group will get pembrolizumab with standard chemotherapy (pemetrexed plus carboplatin or cisplatin). The study will look at how well the treatments work and how safe they are
Study Phase: Phase 3
Principal Investigator: Prof Patrick Forde
Further information

Krystal-4

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Description: This study is testing a new combination of medicines to treat a specific type of lung cancer called non-small cell lung cancer (NSCLC). It focuses on patients who: Have not yet received treatment for their advanced lung cancer. Have a KRAS G12C mutation, which is a change in a gene that can cause cancer cells to grow.
Study Phase: Phase 2
Principal Investigator: Dr Sinead Cuffe
Further information

Krystal-7

A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Description: This trial is recruiting patients with advanced lung cancer . The cancer must have a particular mutation called KRAS G12C. Patients will either receive a new drug called MRTX849 alone or in combination with pembrolizumab
Study Phase: Phase 2
Principal Investigator: Sinead Cuffe
Further information

MK-2870-023

A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer
Description: To compare pembrolizumab with or without maintenance MK-2870 with respect to Overall Survival (OS) Hypothesis (H1): Pembrolizumab with maintenance MK-2870 is superior to pembrolizumab without maintenance MK-2870 with respect to OS To compare pembrolizumab with or without maintenance MK-2870 with respect to PFS per RECIST 1.1 as assessed by BICR Hypothesis (H2): Pembrolizumab with maintenance MK-2870 is superior to pembrolizumab without maintenance MK-2870 with respect t
Study Phase: Phase 3
Principal Investigator: Dr. Sinead Cuffe
Further information

NeoCoast-2

A Phase 2 Open-label, Multicenter, Randomized, Study of Neoadjuvant and Adjuvant Treatment in Subjects with Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer (NeoCOAST-2)
Description: NeoCOAST-2 is a Phase 2 clinical trial testing new combinations of medicines to treat early-stage non-small cell lung cancer (NSCLC) that can be removed with surgery. The goal is to improve outcomes by giving treatment before and after surgery.
Study Phase: Phase 2
Principal Investigator: Prof Patrick Forde
Further information

RELATIVITY (CA224-1093)

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression ≥ 1%
Description: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide, accounting for approximately 18% of all cancer deaths. The introduction of immune checkpoint inhibitors targeting the PD-1 signaling pathway in the treatment of patients with NSCLC has had a significant effect on patient survival. Pembrolizumab combined with chemotherapy in the front-line setting has shown an improvement in overall survival (OS) in NSCLC patients compared to chemotherapy alone.
Study Phase: Phase 3
Principal Investigator: Dr. Sinead Cuffe
Further information

V940-009

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
Description: This Phase 3 study is testing the cancer medicine pembrolizumab alone or together with a vaccine called V940 in people with Stage II to IIIB non‑small cell lung cancer who can have surgery. The study is for people whose cancer did not completely disappear after getting pembrolizumab and chemotherapy before surgery.
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information